Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067002 · ClinicalTrials.gov registry record · Phase 2
Randomized Double Cord Blood Transplant Study
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00067002: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00067002 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 110 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00067002, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.
Primary Outcome
Engraftment is defined as a sustained ANC \> 0.5 x 10\^9/L for at least 3 consecutive days. Engraftment date is the first of the 3 days with sustained absolute neutrophil count (ANC) \>/= 0.5 x 10\^9/L.
Interventions
- DRUG Melphalan
- DRUG Thiotepa
- DRUG Rituxan
- PROCEDURE Expanded allogeneic cord blood (CB)
- PROCEDURE One Unmanipulated and One Expanded Cord Blood Unit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2003-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
What the finished NCT00067002 record still lists
NCT00067002 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00067002 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00067002 about?
NCT00067002 is a clinical study titled "Randomized Double Cord Blood Transplant Study". The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.
What is the current status of trial NCT00067002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2003-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT00067002?
The interventions under investigation include: Melphalan (DRUG), Thiotepa (DRUG), Rituxan (DRUG), Expanded allogeneic cord blood (CB) (PROCEDURE), One Unmanipulated and One Expanded Cord Blood Unit (PROCEDURE).
Who is sponsoring clinical trial NCT00067002?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00067002's enrollment target sits among peer trials
110 632nd of 2000 higher than 1,361 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia